Implementation of mechanism of action biology-driven early drug development for children with cancer
- 31 May 2016
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 62, 124-131
- https://doi.org/10.1016/j.ejca.2016.04.001
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutationsNature Genetics, 2014
- Recurrent activating ACVR1 mutations in diffuse intrinsic pontine gliomaNature Genetics, 2014
- Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened InhibitionCancer Cell, 2014
- Vemurafenib in pediatric patients with BRAFV600E mutated high‐grade gliomasPediatric Blood & Cancer, 2013
- Effective childhood cancer treatment: The impact of large scale clinical trials in Germany and AustriaPediatric Blood & Cancer, 2013
- Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomasNature Genetics, 2013
- Is the European Pediatric Medicine Regulation Working for Children and Adolescents with Cancer?Clinical Cancer Research, 2013
- Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countriesThe Lancet Oncology, 2013
- New drugs for children and adolescents with cancer: the need for novel development pathwaysThe Lancet Oncology, 2013
- Melanoma and Melanocytic Tumors of Uncertain Malignant Potential in Children, Adolescents and Young Adults-The Stanford Experience 1995-2008Pediatric Dermatology, 2010